Hippocampal EUD in primarily irradiated glioblastoma patients

Radiation Oncology

Maximilian Niyazi²  Claus Belka²  Oliver Schnell¹  Silke B Nachbichler²  Gabriele Schupp²  Ute Ganswindt²  Matthias Söhn²  Raphael Bodensohn² 

[1] Neurochirurgische Klinik und Poliklinik, LMU Klinikum der Universität München, Campus Großhadern, Marchioninistr. 15, München, D-81377, Deutschland;Klinik und Poliklinik für Strahlentherapie und Radioonkologie, LMU Klinikum der Universität München, Campus Großhadern, Marchioninistr. 15, München, D-81377, Deutschland

关键词: EUD;    Radiation therapy;    Hippocampus;    Glioblastoma;   

Others  :  1150734
DOI  :  10.1186/s13014-014-0276-5

 received in 2014-10-08, accepted in 2014-11-26,  发布年份 2014

【 摘 要 】

Background

Radiation delivery for malignant brain tumors is gradually becoming more precise. Particularly the possibilities of sparing adjacent normal structures such as the hippocampus are increasing. To determine its radiation exposure more exactly, the equivalent uniform dose (EUD) of the hippocampus was compared with further treatment parameters. This way sparing options could be found.

Methods

From the database of the University hospital of Munich 61 glioblastoma patients were selected who received primary radiotherapy in 2011. General data about the etiology, treatment course, survival of the patients and dose parameters were retrieved.

Results

In a linear regression analysis the side of the tumor (left hippocampus: p < 0.001/right hippocampus: p = 0.009) and its temporal location (left hippocampus: p = 0.015/right hippocampus: p = 0.033) were identified as factors with a significant influence on the EUD of the respective hippocampus. Besides this, the size of the planning target volume (PTV) and the EUD of the hippocampus correlated significantly (p = 0.027; Pearson correlation = 0.291). The median PTV size of the tumor in the right hemisphere was 386.1 ml (range 131.2–910.7 ml), and in the left hemisphere 291.3 ml (range 146.0–588.9 ml) (Kruskal–Wallis test: p = 0.048). A dose quartile analysis showed that 31 patients had a high dose exposure of the hippocampus on one side while having a moderate dose exposure in the other side.

Conclusions

The radiation exposure of the respective hippocampus is dependent on the side where the tumor is located as well as on whether it is temporally located. The exposure of the contralateral hippocampus is further dependent on multiple additional factors – nevertheless a reasonable protection seems to be possible in about half of all cases.

【 授权许可】

   
2014 Bodensohn et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
• [2]Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
• [3]Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014, 370:709-722.
• [4]Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014, 370:699-708.
• [5]Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougere C, Ertl L, Linn J, Herrlinger U, Belka C, Niyazi M: Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neuro-Oncol 2014, 117:337-345.
• [6]Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009, 75:156-163.
• [7]Niyazi M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, Geisler J, la Fougere C, Ertl L, Linn J, Siefert A, Belka C: Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 2012, 82:67-76.
• [8]Wachtel MS, Yang S: Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era. Cancer Med 2014, 3:660-666.
• [9]Balducci M, Fiorentino A, De Bonis P, Chiesa S, Mangiola A, Mattiucci GC, D’Agostino GR, Frascino V, Mantini G, Alitto AR, Colosimo C, Anile C, Valentini V: Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. Strahlenther Onkol 2013, 189:926-931.
• [10]Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC: Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol 2013, 24:3117-3123.
• [11]Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
• [12]Fietkau R, Putz F, Lahmer G, Semrau S, Buslei R: Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution. Strahlenther Onkol 2013, 189:993-995.
• [13]Niyazi M, Schwarz SB, Suchorska B, Belka C: Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Strahlenther Onkol 2012, 188:154-159.
• [14]Fariselli L, Pinzi V, Milanesi I, Silvani A, Marchetti M, Farinotti M, Salmaggi A: Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre. Strahlenther Onkol 2013, 189:456-461.
• [15]Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R: Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012, 13:916-926.
• [16]Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M: Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012, 13:707-715.
• [17]Marsh JC, Godbole R, Diaz AZ, Gielda BT, Turian JV: Sparing of the hippocampus, limbic circuit and neural stem cell compartment during partial brain radiotherapy for glioma: a dosimetric feasibility study. J Med Imaging Radiat Oncol 2011, 55:442-449.
• [18]Gutierrez AN, Westerly DC, Tome WA, Jaradat HA, Mackie TR, Bentzen SM, Khuntia D, Mehta MP: Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys 2007, 69:589-597.
• [19]Marsh JC, Gielda BT, Herskovic AM, Wendt JA, Turian JV: Sparing of the hippocampus and limbic circuit during whole brain radiation therapy: a dosimetric study using helical tomotherapy. J Med Imaging Radiat Oncol 2010, 54:375-382.
• [20]Oskan F, Ganswindt U, Schwarz SB, Manapov F, Belka C, Niyazi M: Hippocampus sparing in whole-brain radiotherapy: a review. Strahlenther Onkol 2014, 190:337-341.
• [21]Raber J, Rola R, LeFevour A, Morhardt D, Curley J, Mizumatsu S, VandenBerg SR, Fike JR: Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res 2004, 162:39-47.
• [22]Pereira Dias G, Hollywood R, Bevilaqua MC, da Silveira da Luz AC, Hindges R, Nardi AE, Thuret S: Consequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptoms. Neuro-Oncology 2014, 16:476-492.
• [23]Gondi V, Tome WA, Mehta MP: Why avoid the hippocampus? A comprehensive review. Radiother Oncol 2010, 97:370-376.
• [24]Giovagnoli AR, Meneses RF, Silvani A, Milanesi I, Fariselli L, Salmaggi A, Boiardi A: Quality of life and brain tumors: what beyond the clinical burden? J Neurol 2014, 261:861-904.
• [25]Kazda T, Jancalek R, Pospisil P, Sevela O, Prochazka T, Vrzal M, Burkon P, Slavik M, Hynkova L, Slampa P, Laack NN: Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol 2014, 9:139. BioMed Central Full Text
• [26]Chera BS, Amdur RJ, Patel P, Mendenhall WM: A radiation oncologist’s guide to contouring the hippocampus. Am J Clin Oncol 2009, 32:20-22.
• [27]Niemierko A: Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 1997, 24:103-110.
• [28]Emami B, Purdy JA, Simpson JR, Harms W, Gerber R, Wippold JF: 3-D conformal radiotherapy in head and neck cancer. The Washington University experience. Front Radiat Ther Oncol 1996, 29:207-220.
• [29]Wu Q, Mohan R, Niemierko A, Schmidt-Ullrich R: Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. Int J Radiat Oncol Biol Phys 2002, 52:224-235.
• [30]Niyazi M, Karin I, Sohn M, Nachbichler SB, Lang P, Belka C, Ganswindt U: Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma. Radiat Oncol 2013, 8:287. BioMed Central Full Text
• [31]Niyazi M, Sohn M, Schwarz SB, Lang P, Belka C, Ganswindt U: Radiation treatment parameters for re-irradiation of malignant glioma. Strahlenther Onkol 2012, 188:328-333.
• [32]Witt JA, Coras R, Schramm J, Becker AJ, Elger CE, Blumcke I, Helmstaedter C: The overall pathological status of the left hippocampus determines preoperative verbal memory performance in left mesial temporal lobe epilepsy. Hippocampus 2014, 24:446-454.
• [33]Armstrong GT, Jain N, Liu W, Merchant TE, Stovall M, Srivastava DK, Gurney JG, Packer RJ, Robison LL, Krull KR: Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. Neuro-Oncology 2010, 12:1173-1186.
• [34]Olsson E, Eckerstrom C, Berg G, Borga M, Ekholm S, Johannsson G, Ribbelin S, Starck G, Wysocka A, Lofdahl E, Malmgren H: Hippocampal volumes in patients exposed to low-dose radiation to the basal brain. A case–control study in long-term survivors from cancer in the head and neck region. Radiat Oncol 2012, 7:202. BioMed Central Full Text
• [35]Ali AN, Ogunleye T, Hardy CW, Shu HK, Curran WJ, Crocker IR: Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme. Radiat Oncol 2014, 9:20. BioMed Central Full Text
• [36]Pinkham MB, Bertrand KC, Olson S, Zarate D, Oram J, Pullar A, Foote MC: Hippocampal-sparing radiotherapy: the new standard of care for World Health Organization grade II and III gliomas? J Clin Neurosci 2014, 21:86-90.
• [37]Evers P, Lee PP, DeMarco J, Agazaryan N, Sayre JW, Selch M, Pajonk F: Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer 2010, 10:384. BioMed Central Full Text
• [38]Chen L, Guerrero-Cazares H, Ye X, Ford E, McNutt T, Kleinberg L, Lim M, Chaichana K, Quinones-Hinojosa A, Redmond K: Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection. Int J Radiat Oncol Biol Phys 2013, 86:616-622.
• [39]Lee P, Eppinga W, Lagerwaard F, Cloughesy T, Slotman B, Nghiemphu PL, Wang PC, Kupelian P, Agazaryan N, Demarco J, Selch MT, Steinberg M, Kang JJ: Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis. Int J Radiat Oncol Biol Phys 2013, 86:609-615.
• [40]Gibbs IC, Haas-Kogan D, Terezakis S, Kavanagh BD: The subventricular zone neural progenitor cell hypothesis in glioblastoma: epiphany, Trojan Horse, or Cheshire fact? Int J Radiat Oncol Biol Phys 2013, 86:606-608.